Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Business Wire
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jennifer Tousignant to the role of Chief Legal Officer.“I am very pleased to welcome Jennifer to Viridian to lead our legal team and join Viridian’s executive team ahead of an exciting set of milestones this year across our thyroid eye disease and anti-neonatal Fc receptor portfolios,” said Steve Mahoney, Viridian President and Chief Executive Officer. “With Jennifer’s deep expertise and long history in public biotech companies advising on a broad set of business and legal matters, she will be a great complement and asset to the team as we execute on our corporate priorities.”Ms. Tousignant joins Viridian most recently from Sana Biotechnology where she was Senior Vice President of Legal and led the legal team res
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024Business Wire
- Foghorn Therapeutics appoints Kristian Humer as chief financial officer [Seeking Alpha]Seeking Alpha
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the FirmPR Newswire
VRDN
Earnings
- 11/13/23 - Beat
VRDN
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- VRDN's page on the SEC website